The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

II-73, has the potential to restore memory and cognitive function in a mouse model of Alzheimer's disease. The study demonstrates that the drug improves memory deficits and reverses brain cell damage, ...

A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has ...

Alzheimer’s disease affects more than 30m people worldwide, mostly the elderly. After the age of 65, the chance of developing ...

Eli Lilly & Company Chairman and CEO Dave Ricks sheds light on growth and success, the increase in weight loss drug ...

Verywell Health's content is for informational and educational purposes only. Our website is not intended to be a substitute ...

Statins help people manage high cholesterol levels, but many experts want to know if these drugs can also support brain ...

The first participants in an international clinical trial aimed at preventing Alzheimer’s disease in young adults at high ...